This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the potential of Arcellx’s CART-ddBCMA (anito-cel) with a focus on the Phase 1 Expansion Trial in Patients with Relapsed/Refractory Multiple Myeloma
Ticker(s): ACLXWho's the expert?
Institution: University of Rochester
- Associate Professor of Medicine and Clinical Director of Multiple Myeloma at The University of Rochester.
- Manages 200 patients with multiple myeloma and also treats patients with other plasma cell disorders.
- Research interests include multiple myeloma and studying disease progression to develop therapies for multiple myeloma prevention.
Interview GoalThis conversation will focus on novel therapies in development for multiple myeloma with a focus on the results presented at ASH 2023 from the Phase 1 Study of Arcellx's Anito-cel for the treatment of patients with relapsed or refractory multiple myeloma.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
